Reduced sensitivity to MDMA-induced facilitation of social behaviour in MDMA pre-exposed rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 4, 2008, Pages 1013-1021

  Thompson, Murray R ^a   Callaghan, Paul D ^a   Hunt, Glenn E ^a   McGregor, Iain S ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

5 HT1A; 8 OH DPAT; Anxiety; Behaviour; MDMA; Social

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; NORADRENALIN; SEROTONIN;

ANIMAL EXPERIMENT; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MEGADOSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; RAT; SENSITIVITY ANALYSIS; SOCIAL BEHAVIOR; SOCIAL INTERACTION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; BODY TEMPERATURE; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PIPERAZINES; PYRIDINES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SOCIAL BEHAVIOR;

EID: 42949085668     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.01.014     Document Type: Article

References (64)

1. Aguirre N., Frechilla D., Garcia-Osta A., Lasheras B., and Del Rio J. Differential regulation by methylenedioxymethamphetamine of 5-hydroxytryptamine1A receptor density and mRNA expression in rat hippocampus, frontal cortex, and brainstem: the role of corticosteroids. J Neurochem 68 (1997) 1099-1105
2. Aguirre N., Ballaz S., Lasheras B., and Del Rio J. MDMA ('Ecstasy') enhances 5-HT1A receptor density and 8-OH-DPAT-induced hypothermia: blockade by drugs preventing 5-hydroxytryptamine depletion. Eur J Pharmacol 346 (1998) 181-188
3. Allott K., and Redman J. Patterns of use and harm reduction practices of ecstasy users in Australia. Drug Alcohol Depend 82 (2006) 168-176
4. Ando R.D., Benko A., Ferrington L., Kirilly E., Kelly P.A., and Bagdy G. Partial lesion of the serotonergic system by a single dose of MDMA results in behavioural disinhibition and enhances acute MDMA-induced social behaviour on the social interaction test. Neuropharmacology 50 (2006) 884-896
5. Australia Institute of Health and Welfare. 2004 National Drug Strategy Household Survey: First Results (2005), AIHW cat. no.PHE 57
6. Baumann M.H., Wang X., and Rothman R.B. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 189 (2007) 407-424
7. Baylen C.A., and Rosenberg H. A review of the acute subjective effects of MDMA/ecstasy. Addiction 101 (2006) 933-947
8. Bull E.J., Hutson P.H., and Fone K.C. Reduced social interaction following 3,4-methylenedioxymethamphetamine is not associated with enhanced 5-HT 2C receptor responsivity. Neuropharmacology 44 (2003) 439-448
9. Bull E.J., Hutson P.H., and Fone K.C. Decreased social behaviour following 3,4-methylenedioxymethamphetamine (MDMA) is accompanied by changes in 5-HT2A receptor responsivity. Neuropharmacology 46 (2004) 202-210
10. Che S., Johnson M., Hanson G.R., and Gibb J.W. Body temperature effect on methylenedioxymethamphetamine-induced acute decrease in tryptophan hydroxylase activity. Eur J Pharmacol 293 (1995) 447-453
11. Clemens K.J., Van Nieuwenhuyzen P.S., Li K.M., Cornish J.L., Hunt G.E., and McGregor I.S. MDMA ("ecstasy"), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat. Psychopharmacology (Berl) 173 (2004) 318-325
12. Clemens K.J., Cornish J.L., Li K.M., Hunt G.E., and McGregor I.S. MDMA ('Ecstasy') and methamphetamine combined: order of administration influences hyperthermic and long-term adverse effects in female rats. Neuropharmacology 49 (2005) 195-207
13. Cornish J.L., Shahnawaz Z., Thompson M.R., Wong S., Morley K.C., Hunt G.E., et al. Heat increases 3,4-methylenedioxymethamphetamine self-administration and social effects in rats. Eur J Pharmacol 482 (2003) 339-341
14. Degenhardt L., Barker B., and Topp L. Patterns of ecstasy use in Australia: findings from a national household survey. Addiction 99 (2004) 187-195
15. Dumont G.J., and Verkes R.J. A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol 20 (2006) 176-187
16. File S.E., and Seth P. A review of 25 years of the social interaction test. Eur J Pharmacol 463 (2003) 35-53
17. Fone K.C., Beckett S.R., Topham I.A., Swettenham J., Ball M., and Maddocks L. Long-term changes in social interaction and reward following repeated MDMA administration to adolescent rats without accompanying serotonergic neurotoxicity. Psychopharmacology (Berl) 159 (2002) 437-444
18. Gartside S.E., McQuade R., and Sharp T. Effects of repeated administration of 3,4-methylenedioxymethamphetamine on 5-hydroxytryptamine neuronal activity and release in the rat brain in vivo. J Pharmacol Exp Ther 279 (1996) 277-283
19. Gerra G., Zaimovic A., Giucastro G., Maestri D., Monica C., Sartori R., et al. Serotonergic function after (+/-)3,4-methylene-dioxymethamphetamine ('Ecstasy') in humans. Int Clin Psychopharmacol 13 (1998) 1-9
20. Gerra G., Zaimovic A., Ferri M., Zambelli U., Timpano M., Neri E., et al. Long-lasting effects of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. Biol Psychiatry 47 (2000) 127-136
21. Granoff M.I., and Ashby Jr. C.R. Effect of the repeated administration of (+/-)-3,4-methylenedioxymethamphetamine on the behavioral response of rats to the 5-HT1A receptor agonist (+/-)-8-hydroxy-(di-n-propylamino)tetralin. Neuropsychobiology 43 (2001) 42-48
22. Green A.R., and McGregor I.S. On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA. Psychopharmacology (Berl) 162 (2002) 448-450
23. Green A.R., Cross A.J., and Goodwin G.M. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology (Berl) 119 (1995) 247-260
24. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., and Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55 (2003) 463-508
25. Gurtman C.G., Morley K.C., Li K.M., Hunt G.E., and McGregor I.S. Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion. Eur J Pharmacol 446 (2002) 89-96
26. Hillegaart V., Magnusson O., and Ahlenius S. A9 and A10 dopamine nuclei as a site of action for effects of 8-OH-DPAT on locomotion in the rat. Pharmacol Biochem Behav 67 (2000) 55-63
27. Huxster J.K., Pirona A., and Morgan M.J. The sub-acute effects of recreational ecstasy (MDMA) use: a controlled study in humans. J Psychopharmacol 20 (2006) 281-290
28. Kalechstein A.D., De La Garza II R., Mahoney III J.J., Fantegrossi W.E., and Newton T.F. MDMA use and neurocognition: a meta-analytic review. Psychopharmacology (Berl) 189 (2007) 531-537
29. Kennett G.A., Marcou M., Dourish C.T., and Curzon G. Single administration of 5-HT1A agonists decreases 5-HT1A presynaptic, but not postsynaptic receptor-mediated responses: relationship to antidepressant-like action. Eur J Pharmacol 138 (1987) 53-60
30. Larsson L.G., Renyi L., Ross S.B., Svensson B., and Angeby-Moller K. Different effects on the responses of functional pre- and postsynaptic 5-HT1A receptors by repeated treatment of rats with the 5-HT1A receptor agonist 8-OH-DPAT. Neuropharmacology 29 (1990) 86-91
31. Levy K.B., O'Grady K.E., Wish E.D., and Arria A.M. An in-depth qualitative examination of the ecstasy experience: results of a focus group with ecstasy-using college students. Subst Use Misuse 40 (2005) 1427-1441
32. Malberg J.E., and Seiden L.S. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 18 (1998) 5086-5094
33. McCambridge J., Mitcheson L., Winstock A., and Hunt N. Five-year trends in patterns of drug use among people who use stimulants in dance contexts in the United Kingdom. Addiction 100 (2005) 1140-1149
34. McCann U.D., Ridenour A., Shaham Y., and Ricaurte G.A. Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology 10 (1994) 129-138
35. McGregor I.S., Clemens K.J., Van der Plasse G., Li K.M., Hunt G.E., Chen F., et al. Increased anxiety 3 months after brief exposure to MDMA ("Ecstasy") in rats: association with altered 5-HT transporter and receptor density. Neuropsychopharmacology 28 (2003) 1472-1484
36. McGregor I.S., Gurtman C.G., Morley K.C., Clemens K.J., Blokland A., Li K.M., et al. Increased anxiety and "depressive" symptoms months after MDMA ("ecstasy") in rats: drug-induced hyperthermia does not predict long-term outcomes. Psychopharmacology (Berl) 168 (2003) 465-474
37. McNamara M.G., Kelly J.P., and Leonard B.E. Some behavioural and neurochemical aspects of subacute (+/-)3,4-methylenedioxymethamphetamine administration in rats. Pharmacol Biochem Behav 52 (1995) 479-484
38. Mechan A.O., O'Shea E., Elliott J.M., Colado M.I., and Green A.R. A neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) to rats results in a long-term defect in thermoregulation. Psychopharmacology (Berl) 155 (2001) 413-418
39. Morgan M.J. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl) 152 (2000) 230-248
40. Morley K.C., and McGregor I.S. (+/-)-3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') increases social interaction in rats. Eur J Pharmacol 408 (2000) 41-49
41. Morley K.C., Gallate J.E., Hunt G.E., Mallet P.E., and McGregor I.S. Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ("ecstasy"). Eur J Pharmacol 433 (2001) 91-99
42. Morley K.C., Li K.M., Hunt G.E., Mallet P.E., and McGregor I.S. Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA ("Ecstasy") in rats. Neuropharmacology 46 (2004) 954-965
43. Morley K.C., Arnold J.C., and McGregor I.S. Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 648-657
44. O'Shea E., Orio L., Escobedo I., Sanchez V., Camarero J., Green A.R., et al. MDMA-induced neurotoxicity: long-term effects on 5-HT biosynthesis and the influence of ambient temperature. Br J Pharmacol 148 (2006) 778-785
45. Parrott A.C. Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 16 (2001) 557-577
46. Parrott A.C. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or ecstasy. J Psychopharmacol 19 (2005) 71-83
47. Parrott A.C., and Marsden C.A. MDMA (3,4-methylenedioxymethamphetamine) or ecstasy: the contemporary human and animal research perspective. J Psychopharmacol 20 (2006) 143-146
48. Picazo O., Lopez-Rubalcava C., and Fernandez-Guasti A. Anxiolytic effect of the 5-HT1A compounds 8-hydroxy-2-(di-n-propylamino) tetralin and ipsapirone in the social interaction paradigm: evidence of a presynaptic action. Brain Res Bull 37 (1995) 169-175
49. Piper B.J., and Meyer J.S. Memory deficit and reduced anxiety in young adult rats given repeated intermittent MDMA treatment during the periadolescent period. Pharmacol Biochem Behav 79 (2004) 723-731
50. Piper B.J., Vu H.L., Safain M.G., Oliver A.J., and Meyer J.S. Repeated adolescent 3,4-methylenedioxymethamphetamine (MDMA) exposure in rats attenuates the effects of a subsequent challenge with MDMA or a 5-hydroxytryptamine(1A) receptor agonist. J Pharmacol Exp Ther 317 (2006) 838-849
51. Price L.H., Ricaurte G.A., Krystal J.H., and Heninger G.R. Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Preliminary observations. Arch Gen Psychiatry 46 (1989) 20-22
52. Reay J.L., Hamilton C., Kennedy D.O., and Scholey A.B. MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes. J Psychopharmacol 20 (2006) 385-388
53. Series H.G., Cowen P.J., and Sharp T. p-Chloroamphetamine (PCA), 3,4-methylenedioxy-methamphetamine (MDMA) and d-fenfluramine pretreatment attenuates d-fenfluramine-evoked release of 5-HT in vivo. Psychopharmacology (Berl) 116 (1994) 508-514
54. Shankaran M., and Gudelsky G.A. A neurotoxic regimen of MDMA suppresses behavioral, thermal and neurochemical responses to subsequent MDMA administration. Psychopharmacology (Berl) 147 (1999) 66-72
55. Soellner R. Club drug use in Germany. Subst Use Misuse 40 (2005) 1279-1293
56. Solowij N., Hall W., and Lee N. Recreational MDMA use in Sydney: a profile of 'Ecstasy' users and their experiences with the drug. Br J Addict 87 (1992) 1161-1172
57. Stone D.M., Merchant K.M., Hanson G.R., and Gibb J.W. Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 26 (1987) 1677-1683
58. Thompson M.R., Li K.M., Clemens K.J., Gurtman C.G., Hunt G.E., Cornish J.L., et al. Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats. Neuropsychopharmacology 29 (2004) 694-704
59. Thompson M.R., Callaghan P.D., Hunt G.E., Cornish J.L., and McGregor I.S. A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 Methylenedioxymethamphetamine (MDMA; "Ecstasy"). Neuroscience 146 (2007) 509-514
60. Topp L., Hando J., Dillon P., Roche A., and Solowij N. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 55 (1999) 105-115
61. Verkes R.J., Gijsman H.J., Pieters M.S., Schoemaker R.C., de Visser S., Kuijpers M., et al. Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology (Berl) 153 (2001) 196-202
62. Vollenweider F.X., Gamma A., Liechti M., and Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naive healthy volunteers. Neuropsychopharmacology 19 (1998) 241-251
63. Walker Q.D., Williams C.N., Jotwani R.P., Waller S.T., Francis R., and Kuhn C.M. Sex differences in the neurochemical and functional effects of MDMA in Sprague-Dawley rats. Psychopharmacology (Berl) 189 (2007) 435-445
64. White B., Degenhardt L., Breen C., Bruno R., Newman J., and Proudfoot P. Risk and benefit perceptions of party drug use. Addict Behav 31 (2006) 137-142